Compass Therapeutics
CMPX
34 hedge funds and large institutions have $85.4M invested in Compass Therapeutics in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 10 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
3.27% less ownership
Funds ownership: 64.85% → 61.58% (-3.3%)
8% less funds holding
Funds holding: 37 → 34 (-3)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
58% less capital invested
Capital invested by funds: $202M → $85.4M (-$116M)
60% less funds holding in top 10
Funds holding in top 10: 5 → 2 (-3)
Top Buyers
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$3.56M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.81M |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
+$620K |
| 4 |
Millennium Management
New York
|
+$56.6K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$51.4K |
Top Sellers
CMPX Hedge Fund Activity: Q1 2022 in Review
34 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Compass Therapeutics (CMPX) for Q1 2022, worth a combined $85.4M — down 58% from $202M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CMPX and 7 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 6 added.
The largest buyer was Janus Henderson Group, adding an estimated $3.56M. The largest seller was RA Capital Management, cutting an estimated $2.72M.
- 34 institutional investors held Compass Therapeutics (CMPX) as of Q1 2022, down from 37 in Q4 2021.
- Funds reported $85.4M of Compass Therapeutics stock for Q1 2022, down 58% quarter-over-quarter.
- 7 funds opened new Compass Therapeutics positions in Q1 2022 and 10 closed out, a net change of -3 holders.
- The largest Compass Therapeutics buyer in Q1 2022 was Janus Henderson Group, an estimated $3.56M added.
- The largest Compass Therapeutics seller in Q1 2022 was RA Capital Management, an estimated $2.72M sold.
Based on aggregated 13F filings for Q1 2022.